Recombinant Human IGF-II Protein, CF

(26 citations)
(1 Review)
  
  • Purity
    >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
  • Endotoxin Level
    <0.10 EU per 1 μg of the protein by the LAL method.
  • Activity
    Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 1.5‑6 ng/mL.
  • Source
    E. coli-derived Ala25-Glu91
  • Accession #
  • N-terminal Sequence
    Analysis
    Ala25
  • Predicted Molecular Mass
    7.5 kDa
292-G2
 
Formulation Lyophilized from a 0.2 μm filtered solution in Acetic Acid.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Data Images
Recombinant Human IGF-II (Catalog # 292‑G2) stimulates cell proliferation in the MCF-7 human breast cancer cell line. The ED50 for this effect is 1.5‑6 ng/mL.
1 μg/lane of Recombinant Human IGF-II was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 7 kDa.
Background: IGF-II

Insulin-like growth factor I (also known as somatomedin C and somatomedin A) and insulin-like growth factor II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved (100% identity between human, bovine and porcine proteins) and exhibit cross-species activity.

IGF-II is a potent mitogenic growth factor. However, unlike IGF-I which has important postnatal roles, the growth-promoting function of IGF-II is limited to embryonic development.

Two specific cell surface receptors that bind IGF-I and IGF-II have been identified. The type I IGF receptor that participates in IGF signaling is structurally related to the insulin receptor. It is a disulfide-linked heterotetrameric transmembrane glycoprotein with an intracellular tyrosine kinase domain. Type I IGF receptor binds IGF-I with higher affinity than IGF-II. The type II IGF receptor which binds IGF-II with much higher affinity than IGF-I is also the cation-independent mannose 6-phosphate receptor. At the present time, it is not known if the type II IGF receptor participates in the IGF signaling pathway. An additional unknown receptor which mediates IGF‑II signaling has also been proposed. Circulating IGFs exist in complexes bound to IGF binding proteins. Currently, at least six high affinity binding proteins have been identified.

  • Long Name:
    Insulin-like Growth Factor II
  • Entrez Gene IDs:
    3481 (Human); 16002 (Mouse)
  • Alternate Names:
    C11orf43; chromosome 11 open reading frame 43; FLJ22066; FLJ44734; IGF2; IGF-2; IGFII; IGF-II; insulin-like growth factor 2 (somatomedin A); insulin-like growth factor II; insulin-like growth factor type 2; MSA; PP9974; somatomedin-A
Related Research Areas
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

26 Citations: Showing 1 - 10
Filter your results:

Species
Applications
Sample Type
  1. CD44(+) fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling
    Authors: Y Liu, C Yu, Y Wu, X Sun, Q Su, C You, H Xin
    J. Cell. Mol. Med., 2017;0(0):.
    Species: Human
    Sample Type:
    Application: ELISA Standard
  2. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases
    Authors: G Cassinelli, E Favini, L Dal Bo, M Tortoreto, M De Maglie, G Dagrada, S Pilotti, F Zunino, N Zaffaroni, C Lanzi
    Oncotarget, 2016;7(30):47848-47863.
  3. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS
    Sci Rep, 2016;6(0):25960.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  4. Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells
    Oncogene, 2016;0(0):.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  5. IGFBP-4 and -5 are expressed in first-trimester villi and differentially regulate the migration of HTR-8/SVneo cells.
    Authors: Crosley, Erin J, Dunk, Caroline, Beristain, Alexande, Christians, Julian K
    Reprod Biol Endocrinol, 2015;12(0):123.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  6. Neurogenin 3 Expressing Cells in the Human Exocrine Pancreas Have the Capacity for Endocrine Cell Fate.
    Authors: Gomez D, O'Driscoll M, Sheets T, Hruban R, Oberholzer J, McGarrigle J, Shamblott M
    PLoS ONE, 2015;10(8):e0133862.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  7. Enhanced memory consolidation in mice lacking the circadian modulators Sharp1 and -2 caused by elevated Igf2 signaling in the cortex.
    Authors: Shahmoradi A, Radyushkin K, Rossner M
    Proc Natl Acad Sci U S A, 2015;112(27):E3582-9.
    Species: Mouse
    Sample Type: Tissue Homogenates
    Application: ELISA Standard
  8. Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells.
    Authors: Gori J, Butler J, Chan Y, Chandrasekaran D, Poulos M, Ginsberg M, Nolan D, Elemento O, Wood B, Adair J, Rafii S, Kiem H
    J Clin Invest, 2015;125(3):1243-54.
    Species: Primate - Macaca nemestrina (Southern Pig-tailed Macaque)
    Sample Type: Whole Cells
    Application: Bioassay
  9. The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis.
    Authors: Laggai S, Kessler S, Boettcher S, Lebrun V, Gemperlein K, Lederer E, Leclercq I, Mueller R, Hartmann R, Haybaeck J, Kiemer A
    J Lipid Res, 2014;55(6):1087-1097.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  10. Insulin-like growth factor 2 enhances regulatory T-cell functions and suppresses food allergy in an experimental model.
    Authors: Yang G, Geng X, Song J, Wu Y, Yan H, Zhan Z, Yang L, He W, Liu Z, Qiu S, Liu Z, Yang P
    J Allergy Clin Immunol, 2014;133(6):1702-8.e5.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  11. Prospectively isolated NGN3-expressing progenitors from human embryonic stem cells give rise to pancreatic endocrine cells.
    Authors: Cai, Qing, Bonfanti, Paola, Sambathkumar, Rangaraj, Vanuytsel, Kim, Vanhove, Jolien, Gysemans, Conny, Debiec-Rychter, Maria, Raitano, Susanna, Heimberg, Harry, Ordovas, Laura, Verfaillie, Catherin
    Stem Cells Transl Med, 2014;3(4):489-99.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  12. Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of alpha-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.
    Authors: Kan S, Troitskaya L, Sinow C, Haitz K, Todd A, Di Stefano A, Le S, Dickson P, Tippin B
    Biochem J, 2014;458(2):281-9.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  13. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.
    Authors: Mancini M, Gariboldi M, Taiana E, Bonzi M, Craparotta I, Pagin M, Monti E
    Br J Cancer, 2014;110(12):2865-73.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  14. A positive autoregulatory BDNF feedback loop via C/EBPbeta mediates hippocampal memory consolidation.
    Authors: Bambah-Mukku D, Travaglia A, Chen D, Pollonini G, Alberini C
    J Neurosci, 2014;34(37):12547-59.
    Species: Rat
    Sample Type: In Vivo
    Application: In Vivo
  15. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
    Authors: Laranjeira AB, de Vasconcellos JF, Sodek L, Spago MC, Fornazim MC, Tone LG, Brandalise SR, Nowill AE, Yunes JA
    Leukemia, 2011;26(5):1001-11.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  16. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.
    Authors: Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuzé-Vourc'h N, Diamandis EP, Courty Y
    J. Biol. Chem., 2011;286(29):25505-18.
    Species: N/A
    Sample Type: N/A
    Application: Enzyme Substrate
  17. A novel type of glial cell in the retina is stimulated by insulin-like growth factor 1 and may exacerbate damage to neurons and Muller glia.
    Authors: Fischer AJ, Scott MA, Zelinka C, Sherwood P
    Glia, 2010;58(6):633-49.
    Species: Chicken
    Sample Type: In Vivo
    Application: In Vivo
  18. CREG inhibits migration of human vascular smooth muscle cells by mediating IGF-II endocytosis.
    Authors: Han Y, Cui J, Tao J, Guo L, Guo P, Sun M, Kang J, Zhang X, Yan C, Li S
    Exp. Cell Res., 2009;315(19):3301-11.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  19. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.
    Authors: Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW
    Proc. Natl. Acad. Sci. U.S.A., 2009;106(24):9826-30.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  20. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Authors: Piao W, Wang Y, Adachi Y, Yamamoto H, Li R, Imsumran A, Li H, Maehata T, Ii M, Arimura Y, Lee CT, Shinomura Y, Carbone DP, Imai K
    Mol. Cancer Ther., 2008;7(6):1483-93.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  21. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways.
    Authors: Hsu E, Feghali-Bostwick CA
    Am. J. Pathol., 2008;172(6):1580-90.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  22. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor.
    Authors: Spicer LJ, Aad PY
    Biol. Reprod., 2007;77(1):18-27.
    Species: Bovine
    Sample Type: Whole Cells
    Application: Bioassay
  23. Association between paternally inherited haplotypes upstream of the insulin gene and umbilical cord IGF-II levels.
    Authors: Adkins RM, Fain JN, Krushkal J
    Pediatr. Res., 2007;62(4):451-5.
    Species: N/A
    Sample Type: N/A
    Application: ELISA Standard
  24. The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori.
    Authors: McCaig C, Duval C, Hemers E, Steele I, Pritchard DM, Przemeck S, Dimaline R, Ahmed S, Bodger K, Kerrigan DD, Wang TC, Dockray GJ, Varro A
    Gastroenterology, 2006;130(6):1754-63.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  25. Long-lasting in vitro hematopoiesis derived from primate embryonic stem cells.
    Authors: Hiroyama T, Miharada K, Aoki N, Fujioka T, Sudo K, Danjo I, Nagasawa T, Nakamura Y
    Exp. Hematol., 2006;34(6):760-9.
    Species: Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
    Sample Type: Whole Cells
    Application: Bioassay
  26. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
    Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
    Biochem. Biophys. Res. Commun., 2005;333(3):1011-6.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
Expand to show all 26 Citations
Average Rating: 5 (Based on 1 review)

Have you used Recombinant Human IGF-II Protein, CF?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Read what people are saying who have used Recombinant Human IGF-II Protein, CF.

We have 1 review tested in 1 application: Binding inhibition assay. I used it as a competitor to saturate the IGF2 binding site to block the IGF2 receptor-mediated endocytosis. .
Filter by Ratings
Excellent
(1)
All Ratings
Filter by Applications
Binding inhibition assay. I used it as a competitor to saturate the IGF2 binding site to block the IGF2 receptor-mediated endocytosis.
(1)
All Applications
Filter by Species
All Species

Images Ratings Applications Species Reviewed By Date Details
  Excellent
 Binding inhibition assay. I used it as a competitor to saturate the IGF2 binding site to block the IGF2 receptor-mediated endocytosis. Anonymous 08/03/2016
Show

Summary

ApplicationBinding inhibition assay. I used it as a competitor to saturate the IGF2 binding site to block the IGF2 receptor-mediated endocytosis.

Other Experimental Details

Other Experimental DetailsCells were seeded in 12-well plates and grown to confluence. Culture medium was replaced with 0.5 ml of EMEM without serum prior to the addition of uptake inhibitors. 5 µg/ml recombinant human IGF-II (R&D Systems; Minneapolis, MN) was applied to the cells for 10 minutes prior to applying purified rhNAGLU-IGF-II at a final concentration of 160 units/ml. Following 4 hours incubation at 37°C and 5% CO2, cells were harvested and intracellular NAGLU activity was measured as described above. The enzyme activity measured in MPS IIIB fibroblasts with rhNAGLU-IGF-II treatment alone was defined as 100% and the intracellular enzyme activity observed in the presence of inhibitor was normalized to rhNAGLU-IGF-II activity. (Biochem J. 2014 458(2):281-9.)

Order Details

    Contact Information

Calculators

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷
R&D Systems Guarantee

Feedback

Customer Information